PharmaEssentia Corporation (TPE:6446)
Taiwan · Delayed Price · Currency is TWD 1,380.00
+15.00 (1.10%)
Nov 13, 2026, 1:30 PM CST
PharmaEssentia Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 24,618 | 15,635 | 9,735 | 5,106 | 2,882 | 656.51 | |
Revenue Growth | 78.20% | 60.61% | 90.67% | 77.15% | 339.00% | 17.81% |
Cost of Revenue | 1,806 | 1,684 | 1,177 | 610.54 | 812.29 | 378.86 |
Gross Profit | 22,812 | 13,950 | 8,558 | 4,495 | 2,070 | 277.65 |
Selling, General & Admin | 8,727 | 5,554 | 4,234 | 4,184 | 2,672 | 1,827 |
Research & Development | 4,153 | 3,468 | 2,588 | 2,224 | 1,426 | 1,273 |
Operating Expenses | 12,882 | 9,022 | 6,822 | 6,408 | 4,098 | 3,100 |
Operating Income | 9,930 | 4,928 | 1,736 | -1,913 | -2,028 | -2,822 |
Interest Expense | -24.65 | -25.53 | -22.19 | -46.69 | -18.53 | -9.97 |
Interest & Investment Income | 572.66 | 649 | 924.06 | 585.13 | 40.44 | 4.63 |
Earnings From Equity Investments | -9.12 | -4.46 | - | - | - | - |
Currency Exchange Gain (Loss) | -571.29 | -571.29 | 376.38 | 375.7 | 122.36 | -1.85 |
Other Non Operating Income (Expenses) | 904.1 | 9.02 | -18.74 | 12.33 | 42.15 | 4.09 |
EBT Excluding Unusual Items | 10,802 | 4,985 | 2,996 | -986.93 | -1,842 | -2,826 |
Gain (Loss) on Sale of Assets | -2.03 | -2.03 | -0.93 | - | -0.1 | -0.07 |
Other Unusual Items | - | - | - | - | - | 14.59 |
Pretax Income | 10,800 | 4,983 | 2,995 | -986.93 | -1,842 | -2,811 |
Income Tax Expense | 1,720 | -62.23 | 29.15 | -363.1 | -467.06 | - |
Net Income | 9,079 | 5,045 | 2,966 | -623.84 | -1,375 | -2,811 |
Net Income to Common | 9,079 | 5,045 | 2,966 | -623.84 | -1,375 | -2,811 |
Net Income Growth | 88.97% | 70.13% | - | - | - | - |
Shares Outstanding (Basic) | 412 | 410 | 408 | 397 | 350 | 320 |
Shares Outstanding (Diluted) | 413 | 412 | 411 | 397 | 350 | 320 |
Shares Change | 0.35% | 0.13% | 3.58% | 13.47% | 9.24% | 7.39% |
EPS (Basic) | 22.04 | 12.30 | 7.27 | -1.57 | -3.93 | -8.78 |
EPS (Diluted) | 21.98 | 12.25 | 7.21 | -1.57 | -3.93 | -8.78 |
EPS Growth | 88.27% | 69.88% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 6,865 | 3,366 | 1,663 | -1,996 | -1,818 | -2,532 |
Free Cash Flow Per Share | 16.62 | 8.18 | 4.04 | -5.03 | -5.20 | -7.91 |
Dividend Per Share | - | 1.352 | 0.894 | - | - | - |
Dividend Growth | - | 51.32% | - | - | - | - |
Gross Margin | 92.67% | 89.23% | 87.91% | 88.04% | 71.82% | 42.29% |
Operating Margin | 40.34% | 31.52% | 17.83% | -37.48% | -70.37% | -429.91% |
Profit Margin | 36.88% | 32.27% | 30.46% | -12.22% | -47.70% | -428.17% |
Free Cash Flow Margin | 27.89% | 21.53% | 17.08% | -39.09% | -63.06% | -385.74% |
EBITDA | 10,153 | 5,061 | 1,847 | -1,824 | -1,912 | -2,703 |
EBITDA Margin | 41.24% | 32.37% | 18.97% | -35.73% | -66.34% | - |
D&A For EBITDA | 223.09 | 133.15 | 110.52 | 89.24 | 116.28 | 119.59 |
EBIT | 9,930 | 4,928 | 1,736 | -1,913 | -2,028 | -2,822 |
EBIT Margin | 40.34% | 31.52% | 17.83% | -37.48% | -70.37% | - |
Effective Tax Rate | 15.93% | - | 0.97% | - | - | - |